Could cost-saving Crohn's theranostic dent anti-TNF sales for Abbvie, Merck?
This article was originally published in Scrip
Theradiag's Lisa-Tracker test for monitoring how well Crohn's disease patients are responding to tumor necrosis factor inhibitors, an expensive class of biologics, has shown it could potentially cut hospital spending on these drugs by up to 25% in France alone. While this spells good news for budget-conscious healthcare payers, it may not be as warmly received by the likes of Merck and Abbvie, whose respective anti-TNF products – Remicade (infliximab) and Humira (adalimumab) – are significant cash cows generating billions of dollars in revenue.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.